DCM
IBRX icon

Delpha Capital Management’s ImmunityBio IBRX Stock Holding History

Delpha Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-864
Closed -$4K – 624
2017
Q4 		$4K Buy
+864
New +$4.09K ﹤0.01% 1350

Other funds holding IBRX

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Delpha Capital Management's IBRX Position: Q1 2018 in Review

Delpha Capital Management sold out of ImmunityBio (IBRX) in Q1 2018, closing a stake of 864 shares — an estimated $4K sold.

Delpha Capital Management first reported a position in IBRX in Q4 2017 and held it in 1 quarter. The position peaked at $4K in Q4 2017. 62 funds tracked by Wall St. Rank hold IBRX as of Q1 2018.

  • Delpha Capital Management reported no remaining ImmunityBio position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 864 ImmunityBio shares in Q1 2018, an estimated $4K.
  • Delpha Capital Management first reported a position in ImmunityBio in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's ImmunityBio position peaked at $4K in Q4 2017.
  • 62 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.